Quantification of corticosteroid-induced skin vasoconstriction: Visual ranking, chromameter measurement or digital imaging analysis

Dermatology

Volumn 205, Issue 1, 2002, Pages 3-10

  Smith, Eric W ^b   Haigh, J M ^a   Surber, C ^c  

^a RHODES UNIVERSITY   (South Africa)

^b OHIO NORTHERN UNIVERSITY   (United States)

^c NONE

Author keywords

Bioequivalence; Chromameter; Corticosteroids; Digital imaging; Vasoconstriction; Visual ranking

Indexed keywords

BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; FLUOCINONIDE;

ACCURACY; BIOASSAY; BIOEQUIVALENCE; CHROMAMETER; CLINICAL TRIAL; DEVICE; DIAGNOSTIC IMAGING; DIGITAL COMPUTER; DRUG HYPERSENSITIVITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; PRIORITY JOURNAL; REVIEW; SKIN BLOOD FLOW; SKIN TEST; STATISTICAL ANALYSIS; VASOCONSTRICTION; VISUAL SYSTEM;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; COLORIMETRY; GLUCOCORTICOIDS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; SKIN; THERAPEUTIC EQUIVALENCY; VASOCONSTRICTION; VEHICLES; VISUAL PERCEPTION;

EID: 0036975937     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063144     Document Type: Review

References (24)

1. Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C: Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 1999;16:909-915.
2. Surber C, Smith EW: The vehicle: The pharmaceutical carrier of dermatological agents; in Gabard B, Elsner P, Surber C, Treffel P (eds): Dermatopharmacology of Topical Preparations. A product-development oriented approach. Berlin, Springer, 1999, pp 5-21.
3. Haigh JM, Smith EW, Meyer E, Fassihi R: Influence of the oil phase dispersion in a cream base on the in vivo release of betamethasone 17-valerate. STP Pharma Sci 1992;2:259-264.
4. Bircher AJ, Hauri U, Niederer M, Hohl C, Surber C: Stealth triamcinolone acetonide in a phytocosmetic cream. Br J Dermatol, in press.
5. Wells GC: The effect of hydrocortisone on standardized skin-surface trauma. Br J Dermatol 1957;69:11-18.
6. Cornell RC, Stoughton RB: Correlation of the vasoconstrictor assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-67.
7. McKenzie AW, Stoughton RB: Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608-610.
8. Haigh JM, Kanfer I: Assessment of topical corticosteroid preparations: The human skin blanching assay. Int J Pharm 1984;19:245-262.
9. Smith EW, Meyer E, Haigh JM: Blanching activities of betamethasone 17-valerate formulations: The effect of the dosage form on topical drug availability. Arzneimittelforschung 1990;40:618-621.
10. Haigh JM, Meyer E, Smith EW, Kanfer I: The human skin blanching assay for in vivo topical corticosteroid assessment. 1. Reproducibility of the assay. Int J Pharm 1997;152:179-183.
11. Haigh JM, Smith EW, Maibach HI: New developments in the methodology available for the assessment of topical corticosteroid-induced skin blanching; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption. New York, Marcel Dekker, 1998, vol 3, pp 487-498.
12. Haigh JM, Meyer E, Smith EW, Kanfer I: The human skin blanching assay for in vivo topical corticosteroid assessment. 2. Subject- and observer-dependent variation in blanching responses. Int J Pharm 1997;152:185-192.
13. Shah VP, Peck CC, Skelly JP: 'Vasoconstriction'-skin blanching assay - A critique. Arch Dermatol 1989;125:1558-1561.
14. Adams WP, Singh GJP: Guidance: Topical dermatologic corticosteroids: In vivo bioequivalence. Division of Bioequivalence, Office of Generic Drugs, Food and Drug Administration, Rockville, 1995.
15. Pershing LK: Assessment of topical corticosteroid-induced skin blanching response using the visual McKenzie-Stoughton and colorimetric methods. Drug Info J 1995;29:923-934.
16. Smith EW, Meyer E, Haigh JM: Accuracy and reproducibility of the multiple-reading skin blanching assay; in Maibach HI, Surber C (eds): Topical Corticosteroids. Basel, Karger, 1992, pp 65-73.
17. Meyer E, Magnus AD, Haigh JM, Kanfer I: Comparison of the blanching activities of Dermovate, Betnovate and Eumovate creams and ointments. Int J Pharm 1988;41:63-66.
18. Meyer E, Smith EW, Haigh JM: Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching. Br J Dermatol 1992;127:379-381.
19. Stoughton RB: Are genetic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987;123:1312-1314.
20. Demana PH, Smith EW, Walker RB, Haigh JM, Kanfer I: Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. Pharm Res 1997;14:303-307.
21. Smith EW, Walker RB, Haigh JM, Kanfer I: Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing - addendum. Pharm Res 1998;15:4-7.
22. Schwarb FP, Smith EW, Haigh JM, Surber C: Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: Comparison of visual and chromameter data. Eur J Pharm Biopharm 1999;47:261-267.
23. Smith EW, Haigh JM, Walker RB: Analysis of chromameter results obtained from corticosteroid-induced skin blanching. 1. Manipulation of data. Pharm Res 1998;15:280-285.
24. Surber C, Smith EW, Schwarb FP, Maibach HI: Drug concentration in the skin; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption. Drugs - Cosmetics - Mechanisms - Methodology. New York, Marcel Dekker, 1999, ed 3, pp 347-374.